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Biochemistry

Effects of Lipid and Glucose on In Vitro Nodule Formation and Calcification by Sheep
Aortic Smooth Muscle Cells.
Director: George Card
Vascular calcification, closely associated with atherosclerosis and diabetes mellitus,
contributes significantly to patient mortality. Diabetes mellitus is characterized by
hyperglycemia and hyperlipidemia. Several in vitro studies have explored the influence
of lipids, particularly 25-hydroxycholesterol, on increased calcification and possible
increased atherosclerotic lesion formation. However, most o f these studies were
conducted at hyperglycemic glucose levels, used an oxidized form of cholesterol and did
not explore a possible interdependence between glucose and lipid on these effects.
Studies to evaluate the effects of lipid and glucose on smooth muscle cells using an
ovine in vitro model were performed in the absence and presence of additional
cholesterol (48.7 mg/dL, 18.8 mg/dL) or triglyceride (173 mg/dL) at both 100 mg/dL
(low) and 450 mg/dL (high) glucose. Nodules, multi-cellular aggregates that calcify in
vitro, were counted and calcium deposition was measured.
Cholesterol increased the number of nodules formed, dose-dependently, and the rate of
nodule formation at both low and high glucose. Triglyceride had a marginal effect.
Cholesterol did not cause significant changes in calcium deposition at either low or high
glucose. The increased nodule formation and rate of nodule formation observed at high
cholesterol was much greater at low glucose, suggesting that glucose influenced the lipid
effects on smooth muscle cell nodule formation.
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1.0 INTRODUCTION
1.1 Introduction
In all tissues except bone, cells actively sequester calcium intracellularly from
ubiquitous phosphate thereby preventing mineralization, the precipitation of calciumphosphate crystals. Dystrophic calcification is the pathological mineralization within soft
tissues, often in response to injury. As a common feature in many pathological conditions
in the vasculature, dystrophic calcification contributes significantly to patient morbidity
and mortality. Dystrophic mineralization in native and bioprosthetic valves is the leading
cause of stenotic (regurgitant) failure, which can cause arrhythmia, stroke and heart
failure

Arterial calcification, used as a predictor of future adverse cardiovascular

events and death, has been positively correlated with atherosclerosis, diabetes, heart
disease, cardiac valve disease, coronary artery disease and with increased risk of
myocardial infarction, unstable angina, dissection after angioplasty and ischemic
episodes in peripheral vascular disease

There is a nearly invariable clinical

association between vascular calcification and atherosclerosis, and advanced
atherosclerosis is frequently associated with diabetes

Most atherosclerotic plaque

ruptures that lead to sudden death are associated with calcification
Despite a frequent role in pathogenesis, vascular dystrophic calcification is an
undefined process with many intricate molecular mechanisms yet to be elucidated.
Calcification has been viewed as a passive process, a direct consequence of cell injury
and/or death dependent only on concentrations of phosphate and calcium that form a
precipitate when mixed

Based on observed similarities between cells and factors

involved in both calcified atherosclerotic plaques and normal bone formation, Demer and

others began in the mid-1990s to rethink the overall process of dystrophic calcification,
suggesting that rather than being a passive process, vascular dystrophic calcification is an
active and regulated process 3, 6, 7, 9 Both physiological (bone) and dystrophic (soft
tissue) calcification involve collagen-associated crystal deposition and initiation of
mineralization in the form of hydroxyapatite (HA) crystals within matrix vesicles, which
are extracellular blebs resembling apoptotic bodies 4-6, 10 xhus apoptosis, regulated cell
death, may be involved

A sub-population of cells from the artery wall with

characteristics o f osteoblasts, the normal bone-building cells, was shown to
spontaneously form mineralized nodules in cell culture, suggesting the cells necessary for
vascular calcification reside in the vasculature

9, 11-13 Such cells are thought to arise

through differentiation of progenitor cell types, such as pericytes, or smooth muscle cells
(SMCs), both of which have been demonstrated to undergo phenotypic modulation. This
supports the notion that there are active regulatory mechanisms shared by bone and
dystrophic calcification

Alkaline phosphatase (ALP), an enzyme that frees phosphate,

and osteopontin (OPN), an HA-binding protein, may be key players, as these have been
detected in vivo in both atherosclerotic plaques and bone, apparently influenced by
several regulating factors common to these sites

4, 5, 9 Both ALP and OPN have also

been found in calcified nodules within vascular cell

c u ltu r e s

14, The regulatory

involvement o f vitamin D, a structurally similar derivative of cholesterol, seems a key to
unraveling the mysterious correlation between osteoporosis and vascular dystrophic
calcification, where bone is being both degraded and produced at different locations
within the same individual 6,7,14

Diabetes mellitus (DM), a pathological condition associated with increased
atherosclerosis, may increase dystrophic calcification through serum factors found at
abnormal levels acting both indirectly and directly on vascular wall cells. Glucose,
insulin, triglycerides and cholesterol are all serum factors that are found at elevated levels
during DM. The mechanisms active in DM may involve oxidized forms of cholesterol
acting through vitamin D receptors, which are found on smooth muscle cells ^^7,14
To elucidate the role that serum factors play in vascular dystrophic calcification
mechanisms and to evaluate potentially exacerbating or therapeutic factors, it is necessary
to examine individual and combined effects of soluble agents in the serum. Diabetic
states of high glucose alone or in conjunction with these other factors may influence the
effect of therapeutic agents on vascular cells. The direct effect of statins, drugs widely
used to lower serum cholesterol, on vascular smooth muscle cell calcification needs to be
evaluated. The increased osteoblastic differentiation by bone cells in response to statins
may also be observed in vascular cells, potentially leading to dystrophic calcification.

1.2 Background and Significance
Several in vitro studies have used subpopulations of cells found in the
vasculature, including SMCs 1’

pericytes

calcifying vascular cells (CVCs)

13 and calcifying valvular cells (CVvCs) H , in efforts to study factors influencing
vascular dystrophic calcification and/or associated disease conditions such as
atherosclerosis and osteoporosis

All these cell types have demonstrated calcification

in cell culture, in the form o f apatite crystals, the same mineral found in vivo in bone and
atherosclerotic plaques. One existing theory is that the mentioned cell types may actually
be the same basic vascular cell derived from SMCs or pericytes. In cell culture, each cell
type mentioned formed spontaneous nodules that subsequently calcified and expressed
osteoblastic differentiation markers, including ALP 1» 3, 9, 11, 12 Calcium deposition
apparently involves phenotypic modulation of vascular cells that differentiate toward
osteoblasts, suggesting a regulated process 3.
Increasing the rates of in vitro calcification by adding increased amounts of the
phosphate donor beta-glycerophosphate p-GP, initially published by Shioi et al, has
become a standard, accelerated method enabling in vitro quantification o f calcification in
dystrophic calcification models 3, 4, 9 Extracellular matrix produced in vitro by bovine
aortic SMCs (BASMCs) accumulates apatitic (calcium phosphate) mineral after p-GP
addition

4, 9 Apatite is deposited along and within collagen fibrils in the presence of

matrix vesicles, correlating to calcified vascular tissues seen in vivo, particularly in
atherosclerotic plaques 1» 4, 9_ The increased BASMC calcification by P-GP is inhibited
by the ALP inhibitor levamisole

Alkaline phosphatase (ALP), which uses p-GP as a

substrate, is required for calcification o f osteoblast, cartilage and smooth muscle cell
cultures in response to P-GP 1. Rat bone marrow stromal cells and mouse clonal
osteoblastic cell lines were shown to form calcified nodules and to express ALP 2,17
Thus, alkaline phosphatase has become a common marker o f osteoblastic differentiation
3 , 5 , 9 , 11.
Interstitial cells cultured from both human and canine cardiac valves (CVvCs)
undergo phenotypic change in vitrOy developing osteoblastic-like characteristics including
alkaline phosphatase (ALP) expression and formation of calcific nodules ^ 1. Mineralized
nodules in cell culture and their association with extracellular bone-building cells
suggests that the cells necessary for vascular calcification reside in the vasculature.
Compared to human, canine CVvCs show decreased time for nodule formation, and
nodules formed from both canine and human sources are morphologically
indistinguishable, suggesting that an animal versus a human model may be preferable in
terms of time and cost ^ ^.
In vitro models demonstrate that the rate of calcification and of nodule formation
can be modified by the addition of soluble factors to vascular cell media. Abnormal lipid
levels and lipoprotein profiles are common in patients with diabetes mellitus

The

presence of 25-hydroxycholesterol (25-OHC) in atherosclerotic plaques and its postulated
regulatory role in bone osteoblast differentiation and matrix production, led to the
investigation o f the lipid role in dystrophic calcification models

The research into

lipid involvement was further prompted by the inhibition of calcification of porcine valve
tissue after selective lipid removal 1^.

25-OHC increased the formation of nodules and the number of calcified (von
Kossa stain positive) nodules by CVvCs ^

The oxidized lipids 25-OHC, oxidized-

low density lipoprotein (ox-LDL) and 8-isoprostaglandin E 2 all increased calcification,
m ineralized nodule formation and ALP activity by CVCs

These oxidized lipids

had the opposite effect on bone pro-osteoblastic cells, suggesting osteoblast-like cells of
the vasculature may respond differently than osteoblasts in bone to identical regulatory
soluble factors

The active form o f vitamin D3, an oxidized derivative of cholesterol,

and dexamethasone, a synthetic glucocorticoid that stimulates osteoblasts in vitro, both
increased calcification, ALP activity and OPN expression by BVSMCs

OPN alone

decreased BVSM C calcification, with no change in ALP activity or phosphorus levels,
and is thought to bind apatite crystals to slow calcification 1.
Hyperglycemia and hyperinsulinemia, both conditions found during diabetes
m ellitus, have a positive and additive effect on human arterial SMC proliferation
Hyperglycemic conditions have been shown to influence VSMC receptor expression
Shioi et al commented that insulin might affect calcification regardless of b-GP addition
Advanced glycation endproducts (AGEs), formed at an accelerated rate during diabetes
m ellitus, are non-enzymatically glycated protein derivatives that are found in
atherosclerotic plaques

AGEs added to bovine pericytes increased the number of

calcified nodules and calcium deposition by approximately the same degree (4x),
suggesting nodule count may be a valid endpoint in evaluating calcification

The

abnorm ally elevated serum components found during diabetes mellitus have been shown

to modulate vascular cells, however, their direct effect on dystrophic calcification by
vascular smooth muscle cells remains unknown.
Statins, competitive inhibitors of the rate-limiting enzyme (HMG-CoA reductase)
of the m evalonate pathway, are currently used to lower levels of serum cholesterol
M evalonate is a precursor of cholesterol and a variety of isoprenoid-containing
compounds. Statins were shown by M undy et al to increase the number of osteoclasts,
the amount of new bone formed and the expression of bone morphogenetic protein 2
(BMP-2) in mouse skull bone cultures 21, 22 The hypothesis is that inhibition of the
mevalonate pathway by statins prevents prénylation and function of small GTPases,
allowing increased BM P-2 expression, causing osteoblast differentiation, proliferation
and enhanced bone formation 21, 22 The direct effect of statins on vascular cell
dystrophic calcification, as yet unknown, may increase osteoblast-like characteristics of
these cells and thereby contribute to mineralization. The complexities of vascular
dystrophic calcification require careful evaluation of multiple factors that may influence
the overall outcome o f therapeutic agents.
Dystrophic calcification appears to be a regulated process, which can be
represented and explored using an in vitro model in which vascular (smooth muscle) cells
form multicellular nodules that subsequently calcify.

1.3 Overall Objective and Hypotheses
The overall objective of this research was to create an in vitro model capable of
evaluating the effect of factors on vascular dystrophic calcification during diabetic and
non-diabetic states. The hypothesis was that blood plasma components found at abnormal
levels in vivo during diabetes mellitus, a diseased state linked to increased rates and/or
risk o f dystrophic calcification, would demonstrate in vitro changes in the rates of nodule
formation and calcification, thus providing insight into the role of these components in
the pathogenesis o f dystrophic calcification in vivo,

1.31 Specific Aims
The following specific aims were designed to address the objectives.
Specific Aim 1: Establish the in vitro model and characterize the nodules.
Specific Aim 2: Determine the correlation between number of nodules and amount of
calcium in culture and evaluate whether this relationship establishes nodule count as a
valid endpoint for measuring dystrophic calcification.
Specific Aim 3: Determine the influence on nodule formation and calcium assay at
elevated levels of glucose (450 mg/dL) exerted by certain factors associated with
increased dystrophic calcification, specifically hypercholesterolemia and
hypertriglyceridemia.
Specific Aim 4: Determine the influence on nodule formation and calcium assay at
baseline levels o f glucose (100 mg/dL) exerted by certain factors associated with
increased dystrophic calcification, specifically hypercholesterolemia and
hypertriglyceridemia.
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2.0 Materials and Methods
2.1 General Materials
Liquid Dulbecco’s modified Eagle’s medium (DMEM, both 450 mg/dL and 100 mg/dL
glucose), fungizone, gentamicin, collagenase type m , liquid trypsin-EDTA, all tissue
culture grade, were obtained from Gibco BRL (Gaithersburg, MD). Fetal bovine serum
(FBS) o f the same lot num ber was acquired from Hyclone (Logan, UT). Calcium assay
kit, D(+) glucose (tissue culture grade) and other chemicals (unless otherwise mentioned)
were obtained from Sigma Chemical Co. (St. Louis, MO). All FBS used was heat
inactivated (30 min at 56°C).

2.2 Cell Harvesting
Sections of sheep aorta were obtained from adult Targhee sheep undergoing experimental
surgical procedures. Outer tissue was gently removed, and the pieces rinsed with DMEM.
The margins were trimmed off and the remainder was cut into approximately 1 mm
pieces, which were placed in 0.1% collagenase in phosphate buffered saline (PBS) and
incubated for 1 hr at 37°C. Following incubation, the supernatant was removed and 10
mL o f DM EM containing 10% FBS was added. The mixture was centrifuged at 1600 rpm
for 5 min and the supernatant was again removed. The cells were resuspended in DMEM
with 10% FBS, gentamicin and fungizone. These primary cultures of Targhee sheep
SMCs were stored frozen at -80°C.
All animals were cared for in accordance with the “Principals of Laboratory
Animal Care” formulated by the National Society of Medical Research, and the “Guide
for the Care and Use of Laboratory Anim als” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published by the National Academy
Press, revised 1996. The use of the animals for this research was also reviewed and
approved by the Institutional Animal Care and Use Committee (lACUC) of the
University of Montana.

2.3 Cell culture
Cells previously harvested from Targhee sheep aorta and frozen back were transferred to
tissue culture plates and maintained in growth medium at 3 T C in a humidified incubator
containing 5% CO 2 , with media exchanged every 2-3 days. Unless otherwise stated,
growth medium was 500mL high glucose DM EM supplemented with 50mL FBS (10%),
0.5mL fungizone, l.OmL gentamicin, 5mL L-glutamine. Low glucose growth medium
refers to growth medium made with low (100 mg/dL) rather than high (450 mg/dL)
glucose DMEM. Cultures capable of forming nodules within 7 days were selected for
experiments and were used up to passage number 15. Prior to seeding cells, cell viability
was quantified by Trypan blue exclusion. Cell counts were performed using a
hemocytometer.

2.4 Experimental Design
Experiments were performed in 24-well tissue culture plates with cells seeded at a
density of 2 x 10^ cells/m L for 24-48 hours (or until confluence) in high glucose growth
m edium (described above) to allow establishment of an equivalent monolayer for all
experiments. For experiments requiring histology, sterile tissue-culture treated coverslips
(Fisher) were placed in each well prior to seeding. After confluence and every 2 days, the
appropriate growth medium (DMEM with high 450 mg/dL or low 100 mg/dL glucose,
10% FBS, fungizone, gentamicin, L-glutamine) was added to wells, followed by addition
o f experimental reagents, at specified concentrations. SMCs were seeded for 24 hours in
DM EM prior to the addition o f lipid. Control wells without additional cholesterol
contained approximately 3.9 mg/dL cholesterol, from the addition of 10% FBS used in
regular DM EM medium. Cholesterol at high (additional 44.82 mg/dL, total 48.72 mg/dL)
and low (additional 14.94 mg/dL, total 18.84 mg/dL) levels was applied within a
commercial suspension high in cholesterol (Sigma Lipids - Cholesterol-rich). The
additional high cholesterol was three times the additional low cholesterol. The source of
triglyceride (Calbiochem triglyceride) was at 43.39 mg/mL, which was used at 40ul/mL
DM EM as high triglyceride, corresponding to 173 mg/dL. After experimental medium
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addition, wells were observed every day for nodule formation. Cells from each
experimental condition and control were evaluated for calcium deposition, at day 3 after
initial nodule formation by the control cells. 5 mM p-glycerophosphate was added to
wells at 3 days prior to calcium assays, to allow a measurable level of calcium. Control
wells without added 5 mM p-glycerophosphate were also evaluated for both nodule
counts and calcium deposition, to control for any influence this substance had in the
presence o f experimental factors. Statistical analysis revealed whether the number of
nodules formed was directly correlated to the amount of calcium deposition, which would
have established the counting o f nodules as an endpoint for easily evaluating calcium
deposition. In subsequent experiments at both high and low glucose concentrations, the
effect o f factors on the average number of nodules formed per well, the rate of nodule
formation, calcium deposition and the presence of calcium in and around nodules were
determined.

2.5 Nodule Visualization
Nodules were observed and counted in wells using an Olympus light microscope at
overall magnification of 40X and lOOX.

2.6 Histology
Cells were stained by standard methods for smooth muscle cell phenotype indicators
including anti-smooth muscle a-actin (positive for SMCs) and von W illebrand stain (v
W F or Factor VUI complex, negative for SMCs). Anti-smooth muscle a-actin (clone
1A4) and polyclonal anti-human von W illebrand factor were acquired from Sigma (St.
Louis, MO).

2.61 a-actin and vWF Stains
To identify SMCs, monolayers were stained with anti-smooth muscle cell a-actin (clone
1A4, 2.5 wL/mL PBS) or von W illebrand Factor (1.33 wL/mL PBS). After a wash with
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PBS-T, coverslips were incubated for 30 min with protein A-horseradish peroxidase, and
then washed again. Staining was visualized using horseradish peroxidase substrate DAB
(Sigma Fast DAB, Sigma, St. Louis, MO). The development was stopped with water and
slides were counterstained with nuclear fast red. Controls were done by replacing either
the antibody or protein A-HP with PBS-T followed by DAB development.

2.62 Qualitative Calcification Visualization/Von Kossa Stain
Cell monolayers on tissue culture treated coverslips were fixed with Histochoice
(Amresco) followed by Von Kossa staining to assess the presence or absence of calcium
in and around SMC nodules. Slides were flooded with 5% aqueous silver nitrate solution,
followed by exposure to UV light for 10-20 min. Slides were then washed 3 times with
deionized water. Unreacted silver was removed by incubating slide for 2 min with 5%
aqueous sodium thiosulfate, followed by another three washes with deionized water.
Counterstaining was done using nuclear fast red exposure for 3-5 min. This technique can
be found in Theory and Practice o f Histotechnology, 2"^ edition, by Sheehan and
Hrapchak, copyright 1980 by B attelle Press.

2.7 MTT Assay
The M TT assay was used to verify non-toxic conditions by measuring mitochondrial
metabolic activity. MTT is a dye that is oxidized by the mitochondria of living cells. 100
uL of SMCs at 2 X 10^ cells/mL were seeded in 96-well flat-bottom microtiter plates for
24 hr at 37^C prior to lipid application for 48hr. 25 uL of 5 mg/mL MTT (3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) in deionized water was then
added to all wells except blanks for 2 hr at 37°C. 100 uL of extraction buffer [20%
sodium dodecylsulfate (SDS)/50% N, N-dimethyl-formamide (DMF)] was then added to
all wells for 12 hr (overnight). Blue wells indicated living cells, yellow wells contained
dead cells. The microtiter plate was then read at 590 nm on a UNIS KAN U microplate
reader (McLean, VA). Control wells contained cells with normal medium, without
additional lipid. Other controls included wells with no cells with no MTT added, wells
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with no cells plus MTT, and wells with cells killed with 50% ethanol plus MTT (dead
cells).

2.8 Calcium Quantifîcation Assay
Cells in 24-well plates treated as described in section 2.4 were seeded and fed with
growth medium supplemented with 5mM (3-glycerophosphate 3 days prior to the calcium
assay. After seeding for 24 hr, lipid in calcification medium was added to experimental
wells. 48-72 hours after addition of lipid, wells showed nodules in approximately the
same distribution as reported for nodule formation counts, with high additional
cholesterol wells showing the greatest number of nodules. Cells were incubated with
0.6 N HCl for 24 hr to solubilize calcium. The digested samples were assayed for calcium
using the o-cresolphthalein complexone reaction which complexes with calcium in
alkaline medium to produce a colorimetric change at 575 nm that was read using a
Beckman DU-6 spectrophotometer with a 570 nm filter.

13

3.0 Statistical Analysis
Effects analyzed statistically were: a.) nodule counts between differently treated
samples, b.) calcium deposition (calcium assay) between differently treated samples, c.)
metabolic activity (MTT assay) between differently treated samples. All experiments
were perform ed in at least triplicate. MTT and calcium assays were also done in duplicate
plates, which demonstrated reproducibility o f these assays. Statistical variance (P) was
determined by the t-test: two sample assuming unequal variances, with statistically
significant results defined as p<0.05.
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4.0 Results
4.1 Establishment of the Experimental Model

SM Cs formed complex multicellular nodules in post-confluent cultures that stained
poorly for a-actin and accumulated calcium deposits.

It was previously established that sheep aortic SMCs are a-sm ooth muscle cell
actin positive and von W illebrand factor negative, and at high passage number (8 to 13)
are capable of forming m ulticelluar nodules that calcify. Sheep aortic fibroblasts and
endothelial cells were incapable of nodule formation, suggesting that nodule formation
only occurs in certain cell types and is not an artifact of tissue culture technique. SMCs
were grown in medium past confluence to develop nodules. Nodules were multi-cellular
aggregations o f cells. In this study, the nodules were then stained for indicators of SMC
characteristics and with Von Kossa to visualize nodule calcification.
Initial experiments were conducted to establish the appropriate growth medium
and conditions for nodule formation. Because the level of fetal bovine serum (FBS)
differs in several in vitro nodule formation models, cells seeded at 2xl0^cells/mL were
exposed to FBS at three different levels, 10%, 15%, 20%, in growth medium, to
determine if FBS affected the number and/or rate o f nodule formation. A level of 10%
FBS resulted in the greatest number and fastest formation of nodules and was therefore
used as the level of FBS in growth media.
Experiments initially using RPM I medium, chosen to allow for varying glucose
levels, revealed that RPMI did not support nodule formation at glucose levels from 0 to
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550 mg/dL (data not shown). DM EM at both low (100 mg/dL) and high (450 mg/dL)
glucose was then selected.
Initially, 153 mg/dL and 18.84 mg/dL were chosen as the high and low cholesterol
levels. However, this level of high cholesterol (153 mg/dL) would not support a SMC
monolayer and appeared toxic to cells. Therefore 48.72 mg/dL was used as the high
concentration for cholesterol. Low cholesterol was kept at 18.84 mg/dL cholesterol. High
cholesterol was three times the amount (45uL) of the cholesterol-rich lipid source as low
cholesterol (15uL) in one mL DMEM.
Nodules were seen in SMC cultures grown in DMEM at approximately 7 days post
confluence. SMC cultures stained positive for a-actin (Figure LB.) and negative for von
W illebrand Factor (Figure 1.A.), an endothelial cell marker, thus establishing these cells
as SMCs. Nodules did not stain well with a-actin (Figure I.C.), indicating a possible
phenotypic change. The nodules tested positive for calcium using the Von Kossa stain
(Figure I.D.). SMCs had to be grown in calcifying medium, containing 5mM betaglycerophosphate, for at least 3 days prior to staining to obtain a test positive for calcium
by the Von Kossa stain. Those cells capable of nodule formation were chosen for
subsequent experiments. The center, but not the periphery, of nodules stained positive
using trypan blue exclusion, whereby dead cells retain a blue color (Figure I.E.).
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4.2 High Glucose Results

Cholesterol increased nodule formation in a dose-dependent manner.
Figure 2.A. shows that addition of cholesterol at both low (18.84 mg/dL) and high
(48.72 mg/dL) levels led to an increase, approximately 7-fold and 21-fold respectively, in
nodule formation over control (3.9 mg/dL, p<0.05). The control value was 22.3 nodules
formed per well at high glucose without additional lipid. The significant three-fold
difference between the cholesterol effects on nodule formation corresponds with the
three-fold differences in additional cholesterol, suggesting a dose-dependent relationship
between cholesterol and nodule formation.

Triglyceride increased nodule formation, but not to the magnitude of the cholesterol
effect.
Figure 2. A. demonstrates that high triglyceride (173 mg/dL) treatment
significantly increased nodule formation approximately three fold over control. Both high
and low cholesterol led to significantly more nodule formation than high triglyceride.

Cholesterol increased the rate o f nodule formation, in addition to the number of
nodules formed.
Increased nodule formation by high cholesterol over control was observed 24 hr
before any significant increase in nodule formation over control by either low cholesterol
or high triglyceride (Figure 2.B.). Triglyceride only increased nodule formation at 48 hr
after lipid addition.
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Cholesterol exhibited no significant effect on SMC calcification at high glucose.
Cholesterol added to SMC cultures grown in calcification media (DMEM plus
5mM b-glycerophosphate) at elevated levels of glucose (450 mg/dL) showed that there
were no significant differences in calcium deposition from the control value with either
low or high cholesterol treatment, as shown in Figure 3.

Cholesterol increased metabolic activity more than triglyceride at high glucose.
Metabolic activity was measured by an MTT assay to determine if lipid levels
were toxic to cells. As shown in Figure 4, metabolic activity increased 1.33-1.35 times
with either low or high cholesterol treatment over the control value (p<0.05). However,
there was no significant difference (< 2 %) in metabolic activity between low and high
cholesterol treatments. Metabolic activity significantly increased 1.21 times over control
with the addition of high triglyceride (Figure 4). This increase in metabolic activity with
high triglyceride treatment was to a small ( 1 0 - 1 2 %), but significant, magnitude less than
with either low or high cholesterol treatment (p<0.05). The levels of lipids applied were
not toxic to the cells at high glucose.
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4.3 Low Glucose Results

High cholesterol increased nodule formation much more than either low cholesterol
or triglyceride at low glucose.
In order to determine the influence on nodule formation at low levels of glucose
(100 mg/dL) exerted by certain factors associated with increased dystrophic calcification,
cholesterol and triglyceride were added as described previously, this time to SMC
cultures seeded for 24 hours in high glucose DMEM, then fed with or without lipid in
low glucose DMEM.
At low glucose, the 2.4-fold increase in nodule formation over the control (8.7
nodules) upon treatment with low cholesterol was not significant (Figure 5.A.). However,
nodule formation increased 28-fold over control with the addition of high cholesterol
(p<0.05). There were 12 times more nodules with high cholesterol treatment than with
low cholesterol treatment (p<0.05).
At low glucose, there were no significant differences in the number of nodules
formed between the following treatments (Figure 5.A.): control and high triglyceride, low
cholesterol and high triglyceride and between control and low cholesterol. At low
glucose, as previously seen at high glucose (see Figure 2. A. for this 7-fold increase), high
cholesterol increased nodule formation significantly (22.4 times) more than high
triglyceride.
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H igh cholesterol increased nodule formation to a greater magnitude in low glucose
than in high glucose conditions.
As shown in Figure 5.B., there were 18.2 times more nodules upon treatment with
high cholesterol than the control value of 5.3 nodules. In comparing low glucose with
high glucose results in terms of nodule formation, Figure 5.B. shows that there were no
significant differences between low and high glucose at control, low cholesterol and high
triglyceride. The most striking result, as demonstrated in Figure 5.B., was at high
cholesterol, there were 2.5 times more nodules formed at low glucose than at high
glucose (p<0.05).
There were no significant differences from control in the number of nodules
formed with high triglyceride treatment at either low or high glucose (Figure 5.B.).
However, Figure 2 showed a slight (3-fold) significant increase in nodule formation at
high glucose with high triglyceride over control. At low glucose, there was no significant
change (1.9-fold) between low cholesterol and high triglyceride treatments, unlike at high
glucose where 3.2-fold and 2.3-fold increases with low cholesterol were seen over high
triglyceride in Figure 5.B and Figure 2, respectively. At low glucose, there was a
significant (22.4-fold) increase in nodule formation with high cholesterol versus high
triglyceride treatment, an increase also seen at high glucose in both Figure 5.B. (11.2
times) and in Figure 2. A. (7 times). At low glucose, cholesterol increased the rate of
nodule formation compared to control within 24 hr. W ithin 48hr, this observation was
also made at high glucose (Figure 5 C).
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Cholesterol did not cause significant changes in calcium deposition by SMCs under
low glucose conditions.
In order to determine the influence on calcium deposition and metabolic activity
at low glucose (100 mg/dL) exerted by certain factors associated with increased
dystrophic calcification, cholesterol and triglyceride were added to SMC cultures seeded
24 hr in high glucose DMEM, then fed with lipid in low glucose DMEM. Calcium
deposition was then measured after dissolving the monolayer in 0.6N HCl for 24 hr.
The addition of cholesterol did not result in any increase in calcium deposition at
low glucose (Figure 6 .A.). There were no significant changes in calcium deposition
between control and low or high cholesterol treatments, or between low and high
cholesterol treatments.
Figure 6 .B. shows the results o f calcium assays with lipid treatments at both low
and high glucose. There was no significant difference between low glucose and high
glucose controls. Glucose alone or cholesterol alone did not influence calcium deposition
(Figure 6 .B.). At high glucose, either low or high cholesterol seemed to increase calcium
deposition. At low glucose, the presence of either low or high cholesterol appeared to
decrease calcium deposition. Decreased glucose in the presence of either low or high
cholesterol exhibited an inverse relationship to calcium deposition. W ith additional
cholesterol, lowering glucose appeared to decrease calcium deposition by 2.6-2.7 fold
(p>0.05). However, the control values (absorbance at 570 nm) under low glucose and
high glucose showed large variation, so the glucose effect on calcium deposition was
inconclusive.
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Cholesterol increased metabolic activity at low glucose, whereas triglyceride did not
increase metabolic activity.
Figure 7.A. shows the effect o f lipid on metabolic activity under conditions of low
glucose. At low glucose, there was a slight (0.95 times) decrease from control upon high
triglyceride treatment. There was a 1.42-fold increase in metabolic activity upon high
cholesterol treatment over control and a 1.49-fold increase with high cholesterol versus
high triglyceride treatment (p<0.05). The levels of lipids applied were not toxic to the
cells at low glucose.

High glucose alone increased metabolic activity.
The lipid effect on metabolic activities at both low and high glucose is shown in
Figure 7.B. Control values (absorbance at 590 nm) were 0.750 for low glucose and 0.805
for high glucose. High glucose control was 1.07 times greater than low glucose control
(p<0.05), thus high glucose alone increases metabolic activity. At high glucose,
significant 1.33 and 1.2 times increases in metabolic activity over control were observed
with high cholesterol treatment and with high triglyceride treatment, respectively.
Treatment with high cholesterol gave 1.1 times (10%) higher metabolic activity than
treatment with high triglyceride (p<0.05). A significant 1.36-fold decrease in metabolic
activity from high glucose to low glucose conditions with high triglyceride was
noticeable. There was no significant difference between low and high glucose in
metabolic activity with high cholesterol treatments.
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5.0 Figures

Figure l.A . Sheep smooth muscles cells did not stain positive for von Willebrand
factor 7 days after confluence. M agnification 40X.
V

-'I.

Figure l.B . Sheep smooth muscles cells stained positive for smooth muscle cell a-actin
7 days after confluence. Magnification 40X.
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Figure l.C . Sheep smooth muscles cells and nodule stained for smooth muscle a-actin,
counterstained with nuclear fast red 7 days after confluence. The nodule did not stain
positive for a-actin, whereas the surrounding SMCs did. Magnification 40X.

f :

Figure l.D . Sheep smooth muscles cells and nodule stained by Von Kossa 7 days after
confluence, 3 days after application o f calcification media. Brown areas, concentrated
within the nodule, are calcified. Magnification 40X.
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Figure I.E. Sheep smooth muscles cells and nodule stained by trypan blue exclusion 7
days after confluence. Blue cells, concentrated in the nodule, are non-viable.
M agnification 40X.
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Lipid Effect on Nodule Form ation by S m ooth
M uscle Cells a t High G luçose
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Figure 2.A. Lipid effect on the average number o f nodules formed per well by
SMCs at high (450 mg/dL) glucose, two days after lipid treatment. Error = s.d., * =
significant increase over control, n = 6 .
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Figure 2.B. Lipid effect on the average number o f nodules formed per well by
SM Cs at high glucose, one to five days after lipid treatment. Error = s.d., * =
significant increase over control, n = 6 .
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Lipid Effect on Calcium Déposition by Smooth
Muscle Cells at High Glucose
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Figure 3. Calcium deposition by SMCs 2 days after treatment with lipid at high
glucose, as measured by the average absorbance at 570 nm per well. Error = s.d.,
n= 8 , p>0.24.
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Figure 4. Lipid effect on metabolic activity at high glucose, as measured with
M TT assay as the average absorbance at 590 nm per well. Error = s.d., n= 8 .
*=p<0.005 over control.
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Lipid Effect on Nodule Formation by Smooth Muscle
Cells at Low Glucose
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F ig u re 5.A. Lipid effect on the average number o f nodules formed per well by
SMCs at low glucose 2 days after lipid treatment. Error = s.d., * = significant
increase over control (p<0.05), n = 3.
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Lipid Effect on Nodule Formation at High and Low
Giucose
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Figure 5.B. Lipid effect on the average number o f nodules formed per well by
SMCs at low and high glucose 2 days after lipid treatment. Error = s.d., * =
significant increase over control (p<0.05), n = 3.
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Figure 5.C. Lipid effect on the average number o f nodules formation by SMCs at
low and high glucose from one to four days after lipid treatment. Error = s.d., * =
significant increase over control (p<0.05), n = 3.
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Figure 6.A. Calcium deposition by SMCs 2 days after treatment with lipid at high
glucose. Error = s.d., n= 8 , p>0.08.
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Figure 6.B. Calcium deposition, as measured by absorbance at 570 nm, by SMCs 2
days after treatment with lipid at low and high glucose. Error=s.d., n= 8 , ^ denotes
significant decrease at low versus high glucose.
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Lipid Effect on Smooth Muscle Cell Metabolic Activity
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Figure 7.A. Metabolic activity o f SMCs, two days after lipid treatment, as measured
w ith MTT assay. Error=s.d., n= 8 , *=p<0.046 over control.
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Figure 7.B. Metabolic activity o f SMCs at high and low glucose, as measured with
M TT assay as absorbance at 590 nm, two days after lipid treatment. Error = s.d., n= 8 ,
* = significant increase over control.
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6.0 Discussion
The present investigation was aimed at understanding some of the cellular
m echanisms o f atherosclerotic plaque formation and subsequent calcification, in
particular those serum factors that may mediate these processes that are present at
elevated levels as seen in diabetes mellitus, a disease state closely associated with
increased rates of atherosclerosis. The hypothesis was that serum factors found at
elevated levels during diabetes mellitus, such as lipid and glucose, would increase both
nodule formation and calcification, thereby suggesting a role in atherosclerosis in vivo.
Cholesterol increased the number o f nodules formed, but did not increase or
influence calcification of these nodules at either low or high glucose levels. The increase
in nodule formation found at high cholesterol levels was influenced by glucose
concentration, with low glucose causing a greater number of formed nodules than at high
glucose.
The hypothesis that increased lipid leads to increased nodule formation was
supported. At high glucose, addition of cholesterol or triglyceride increased nodule
formation. Cholesterol resulted in a more significant increase in nodule formation than
triglyceride. Nodule formation appeared to have a dose-dependant positive response to
cholesterol. Thus, specific lipids at particular levels may influence an increase in
atherosclerotic lesion formation in vivo.
The Demer group has demonstrated that CVCs increased nodule formation upon
application o f an oxidized form of cholesterol, 25-hydroxycholesterol (25-OHC)
From the results presented in this thesis, it appears that unoxidized cholesterol is also
capable of increasing nodule formation. However, it is possible that cholesterol in our
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system was converted to the oxidized form. An experiment that tested the effect of both
unoxidized and oxidized cholesterol on nodule formation using this system would
indicate whether further tests on oxidation state were required. The hypothesis would be
that oxidized cholesterol causes an increase in calcification and unoxidized cholesterol
causes no change in calcification. If both oxidized and unoxidized cholesterol both
changed or did not change calcification, then further testing of the oxidized states of the
cholesterol would be required. Other lipids have been shown to increase both nodule
formation and calcification by vascular cells, particularly 25-hydroxycholesterol (25OHC)

Many researchers have explored the effect of oxidized lipids on vascular cells.

Other oxidized lipids, such as ox-LDL, were shown to increase nodule formation by
vascular cells

In the experiments with ox-LDL, researchers found no increase in

nodule formation by unoxidized lipids

Our research demonstrates that at either high or

low glucose, the unoxidized lipid cholesterol increased the number of nodules formed,
whereas triglyceride lipids had little or no influence on nodule formation.
The addition of low or high cholesterol or triglyceride showed no significant
changes in nodule calcium deposition over control. Cholesterol or lipid did not influence
calcification at either low or high glucose, which contradicts our hypotheses regarding
calcification. Contrary to our hypothesis, nodule count and calcium levels found in
culture do not appear to be related. This differs from previous findings, where serum
factors, such as 25-OHC, were found to increase both nodule formation and calcium
deposition by CVCs^^. In vitro, oxidized forms of cholesterol can increase both nodule
formation and calcification, whereas unoxidized cholesterol only appears to increase
nodule formation with no change in calcification. In vivo, increased cholesterol in serum
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contributes to early abnormalities in VASM Cs that develop into atherosclerotic lesions.
Over time, cholesterol accumulating in these lesions becomes oxidized, and perhaps it is
the oxidized form of cholesterol, 25-OHC, rather than the unoxidized form, which
contributes to increased calcification of the atherosclerotic plaque. Data collected from in
vivo atherosclerotic plaques revealed increased levels of 25-OHC. This, along with the
current data, suggests that in vivo, unoxidized cholesterol can increase atherosclerotic
lesion formation, but that the oxidized form o f cholesterol, formed later, is required to
increase calcification of atherosclerotic lesions and plaques.
Oxidized lipids were chosen by previous groups due to their known role in
osteoblast stimulation during bone formation. This connection to osteoblasts was made
by other groups, including Demer et al, when smooth muscle and other vascular cells
were shown to undergo a phenotypic change in the direction of osteoblasts when forming
nodules 6 , 7, 12,13 Our data indicated a possible phenotypic change in cells involved in
nodule formation, as nodules did not stain well with a-actin. Other phenotypic markers
such as alkaline phosphatase (ALP) would provide a better indication whether phenotypic
change was in the direction of osteoblasts. Other groups, including Demer et al, noted
this phenotypic change in the course of nodule formation and suggested differentiation of
SMCs toward osteoblast-like cells 12,13. The differentiated state of intimai SMCs within
atherosclerotic lesions in vivo is often altered. Several groups have noted osteoblast-like
characteristics developed in those cells forming nodules, including loss of normal SMC
markers, and increased expression o f osteoblast markers such as ALP. Anti-H-caldesmon
may also be used to verify SMC phenotype and to distinguish from myofibroblasts and
pericytes.
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Previous research on the lipid effect on nodule formation and calcification by
vascular cells was nearly exclusively carried out in vitro at diabetic or higher levels of
glucose. To ascertain whether the increased nodule formation at high cholesterol was
influenced by glucose concentration, nodules subjected to high cholesterol and control
(no additional lipid) were counted at both low (lOOmg/dL) and high (450mg/dL) levels of
glucose. There was an influence of glucose on nodule formation, yet this influence was in
conjunction with high cholesterol. At high cholesterol, the number of nodules formed at
low glucose was considerably more than the number formed at high glucose. Cholesterol
at low glucose increased nodule formation only when at a level which was nearly 3 times
higher than that required for significant increase on nodule formation seen at high
glucose. This suggests that high glucose stimulates the increased effect of low levels of
cholesterol on nodule formation, i.e. glucose and low cholesterol appear to work in a
cooperative m anner on nodule formation. Nodule formations at both high and low
glucose (see Figures 2 and 5.B.) were significantly increased over controls with the
addition o f high cholesterol, and there was a significant increase in nodule formation
between low and high cholesterol. However, under conditions of high cholesterol in vitro,
decreased levels of glucose (lOOmg/dL) demonstrated a greater increase in nodule
formation over controls than observed at elevated glucose (450mg/dL). Previous studies
have been conducted at high glucose levels and have failed to explore this cholesterolglucose relationship.
The cholesterol effect on nodule formation by ASMCs was clearly influenced by
the concentration of glucose. This may be related to situations seen in vivo during
prolonged diseased states. In diabetes mellitus, prolonged elevated serum levels of
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glucose affect insulin levels and/or functionality, which creates a starvation state for
vascular cells, i.e. glucose is unable to be brought into cells with the help o f insulin at
normal (non-diseased) rates. Perhaps this in vitro increase in the high cholesterol effect
on nodule formation at low glucose versus high glucose reflects an increased effect o f
cholesterol on SMC abnormalities (atherosclerotic lesions) when adequate glucose is not
available to vascular cells. There is an underlying implication that alternate metabolic
pathways, i.e. those utilizing cholesterol versus glucose, may contribute to nodule
formation, or are at least somehow involved, perhaps through glycolytic metabolite
shunting into alternate pathways.
There were no significant changes in calcium deposition either from low or high
cholesterol treatment above control or between low and high cholesterol at both high and
low glucose levels. However, significant, albeit small, increases at high versus low
glucose were seen in calcification to an equivalent degree at both low and high
cholesterol levels (Figure 6 .B.). Thus unoxidized cholesterol at both low and high
concentrations may exhibit a small influence on calcification at low glucose not
demonstrated at high glucose. It would be interesting to see if 25-OHC at high and low
glucose would show this difference.
In establishing this in vitro model, RPMI, the first chosen medium, did not
support nodule formation, whereas DMEM did. There are multiple differences between
the two media, however there are some specific differences that may have contributed to
this effect that may be worth exploring. DM EM has 4.00 mg/L thiamin HCl whereas
RPMI has only 1.00 mg/L. Thiamine (vitamin B l) is important in glucose metabolism as
a coenzyme that shunts glycolysis metabolites, specifically 3-phosphoglyceraldehyde into
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the pentose phosphate pathway and pyruvate into the Krebs cycle. The inability of RPMI
to allow for nodule formation may be due to a lack of adequate vitamin B 1 that would
allow shunting o f glycolysis metabolites. There are several differences in the vitamin
levels of these media, with DM EM containing far greater amounts of several vitamins
necessary to glucose metabolism than RPMI. For example, there is a greater amount of
D-Ca pantothenate, a precursor to Coenzyme A, in DMEM (4.00 mg/L) than in RPMI
(0.250 mg/L). Since HM G-CoA is a precursor to mevalonate, which eventually forms
cholesterol, this may be important. Exploring the specific differences in vitamins that
allow nodule formation may indicate specific pathways used or shunted.
At high glucose, significant increases over control in metabolic (mitochondrial)
activity were seen upon addition o f cholesterol (see Figure 4.A.). Originally the MTT
assay, which measured a dye that is changed in the mitochondria (indicating
m itochondrial activity) was simply used to show that the levels of lipids chosen were not
toxic to cells. The cells were viable at both low and high cholesterol levels, so neither
calcification nor nodule formation was associated with, or could be explained by,
increased cell death. There was no significant difference in metabolic activity between
low and high cholesterol application. This could be due to low cholesterol producing the
m axim um metabolic activity observable by this assay. Differences in
metabolic/mitochondrial activity may be evident upon further tests with more sensitive
assays. There was no significant change in either metabolic activity or calcium deposition
between low and high cholesterol treatments. Metabolic activity changes did not appear
to explain either the increases in nodule formation demonstrated between low and high
cholesterol treatments (see Figure 2.A.), or the lack of significant differences over control
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demonstrated in calcium deposition (see Figure 3). The MTT information does not
support nor refute the original theory of calcification, which states that increased
calcification is due to increased cell death, and is a simple process of ubiquitous
phosphate forming apatite upon release of calcium from dead cells.
Our use of MTT demonstrated that the change in nodule formation between low
and high glucose at high cholesterol could not be explained by changes in mitochondrial
activity. The MTT assay has been used with other cell types to measure proliferation, but
was not intended for that purpose in this study. Accelerated proliferation of the normally
quiescent VSMCs is known to contribute to atherosclerotic lesion formation. Previous
findings gave mixed results when attempting to correlate nodule formation and
proliferation activity. Further studies utilizing other indicators more accurate for
m easuring proliferation such as PCNA stain or BrdU may give better indication of actual
proliferation state, and would be o f interest.
Unoxidized cholesterol increased the number of nodules formed by vascular
smooth muscle cells but did not influence calcification. At high cholesterol, glucose
exhibited an influence on the number of nodules formed, with increased glucose
somehow limiting the increase in nodule formation due to cholesterol.
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7.0 Conclusion
This investigation was undertaken to elucidate some of the molecular mechanisms
of atherosclerotic plaque formation and subsequent calcification. The serum factors
glucose, cholesterol and triglyceride were evaluated because they may influence these
processes due to their elevated levels during diabetes mellitus, a disease state closely
associated with increased rates of atherosclerosis.
The results o f this study demonstrated that cholesterol increased nodule formation
in a dose-dependent fashion, and the rate of nodule formation at both high and low
glucose. Triglyceride had these same effects, but to a much smaller magnitude.
Cholesterol did not cause significant change in calcium deposition at either low or high
glucose. Either a better calcium assay, such as Ca"^^, or normalizing the calcium
deposition to the amount of protein, as was done by other groups, may reveal results
more closely resembling that of other groups using 25-OHC

1^. The increased

nodule formation and rate of nodule formation observed at high cholesterol was much
greater at low glucose, revealing that glucose influenced the lipid effects on smooth
m uscle cell nodule formation. The number of nodules formed was not determined to be
an indication of the level of calcification in cell culture.
These results suggest that atherosclerotic lesion formation and calcification may
occur through different mechanisms. Unoxidized cholesterol may contribute to early
atherosclerotic lesion formation in vivo, as indicated by increased nodule formation in
vitro. Perhaps oxidized cholesterol, in the form of 25-OHC, is required for increased
calcification o f atherosclerotic plaques. The oxidized 25-OHC may act through vitamin D
receptors to increase calcification, as has been hypothesized by Demer et al, whereas
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unoxidized cholesterol may act through scavenger receptors found on SMCs to increase
atherosclerotic lesions 6 , 7,13 The increase in nodule formation at low versus high levels
of glucose implies that starvation for glucose states, such as those found during insulin
resistance in diabetes mellitus, may modulate lipid effects on vascular cells. Future
studies should be conducted using this model to determine whether 25hydroxycholesterol, versus unoxidized cholesterol, increases calcium deposition, thereby
suggesting that only oxidized cholesterol influences the later atherosclerotic mechanism
of calcification. Testing unoxidized cholesterol and 25-OHC in the presence and absence
of vitamin D receptor anti-bodies may shed light on whether these receptors are required
for the increased calcification seen previously with 25-OHC. The glucose influence on
the lipid effects on nodule formation by vascular cells emphasizes the need for exploring
this effect when experimenting with those factors affecting cholesterol effects on vascular
cells.
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